Pleasanton CA, Singapore, and Tokyo, January ___/PRNewswire/ — TriReme Medical, Inc. (TriReme)
today announced that it has signed an exclusive distribution and sales agreement for TriReme’s
complete line of advanced peripheral and coronary balloon dilatation catheters with Century Medical,
Inc. (CMI), a leading independent device distributor for the important Japanese market.

Singapore, January 11, 2011 – MerLion Pharmaceuticals Pte Ltd today
announced the signing of an agreement with Alcon Pharmaceuticals, Ltd. an
affiliate of Alcon, Inc., by which Alcon obtains exclusive rights from MerLion
for the development and commercialization in North America of finafloxacin
specifically for treating ear infections.

SINGAPORE, Jan. 5, 2011 – To enable millions of new artists in Asia to be part of worldclass content productions, Gobi Partners, Inc., a leading digital media and technology
venture firm in Asia and Singapore’s EDB Investments Pte Ltd., invest US$6 Million in
Cloudpic® Global Inc., a pioneering leader in cloud computing applications for the digital
entertainment industry.

Norderstedt – 29 November 2010 – Triton Water AG (“Triton”) has announced that EDB
Investments (“EDBI”) of Singapore is investing in Triton, the leading provider of complete
water-cycle industrial and maritime water treatment solutions, backed by zouk ventures.

Singapore, October 18, 2010 – S*BIO Pte Ltd today announced that the European Commission (EC)
has granted orphan drug designation to SB1518, its potent and orally active JAK2 inhibitor for the
treatment of primary myelofibrosis (PMF), post-polycythemia vera myelofibrosis (PPV-MF) and postessential thrombocythemia myelofibrosis (PET-MF). SB1518 has also received orphan drug designation
from the U.S. Food and Drug Administration (FDA) for the treatment of the same disorder

Pleasanton, CA – October 11, 2010 – TriReme Medical, a leading developer of innovative
catheters and stents for the treatment of complex vascular disease, announced today the
closing of a $17M Round D financing.

Inviragen and PharmaJet announced the award of a five year, $15.5 million dollar
contract from the National Institute of Allergy and Infectious Diseases (NIAID), part of the
National Institutes of Health (NIH), to advance the development of a needle-free, easy to
administer dengue vaccine. The award will fund preclinical studies, regulatory filings,
manufacturing and clinical testing of Inviragen’s tetravalent dengue vaccine, DENVax™
delivered with PharmaJet’s convenient needle-free injection device.

SINGAPORE, Sept. 27, 2010 – S*BIO Pte Ltd today announced the initiation of a Phase 2 clinical trial
of SB939, its novel orally-active HDAC inhibitor, in patients with recurrent or metastatic prostate
cancer (HRPC).

SINGAPORE, Sept. 23, 2010 – S*BIO Pte Ltd today announced a US$5 million investment by Mitsui
Ventures that will support the continued development of S*BIO’s clinical programs.

Company Commits New Product Line to Support
USDA Agricultural Research Service’ s “ Penny-perData-Point” Program for High Sample Throughput
Genotyping